Rethinking the adenosine-A_2AR checkpoint: implications for enhancing anti-tumor immunotherapy

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Adenosine signaling through adenosine A2A receptors (A2AR) negatively regulates immune responses.
• Tumors exploit this pathway to evade immune surveillance, presenting A2AR as a potential target for cancer immunotherapy.
• Preclinical studies in mice show promise, but clinical translation has yielded limited success.

Purpose of the Study:

• To review the mechanisms of adenosine-A2AR signaling in immune regulation and anti-tumor immunity.
• To identify discrepancies between preclinical findings and clinical outcomes of A2AR-targeted therapies.
• To reveal opportunities for enhancing the translational success of A2AR-targeted immunotherapies.

Main Methods:

• Literature review of preclinical and clinical studies on adenosine-A2AR signaling in cancer.
• Analysis of the impact of A2AR on various immune and stromal cells within the tumor microenvironment.
• Examination of clinical trial data for A2AR inhibitors in immunotherapy-resistant patients.

Main Results:

• Adenosine-A2AR signaling broadly suppresses immune cell function and promotes immune evasion in tumors.
• Limited clinical efficacy of A2AR antagonists has been observed, particularly in patients resistant to other immunotherapies.
• Responses in some patients suggest the pathway's involvement in tumor immune evasion.

Conclusions:

• Despite preclinical promise, the clinical translation of adenosine-A2AR blockade for anti-tumor immunity faces challenges.
• Understanding the specific roles and contexts of adenosine-A2AR signaling is crucial for optimizing therapeutic strategies.
• Further research is needed to bridge the gap between mouse models and human clinical outcomes for A2AR-targeted immunotherapies.